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Abstract
Objective: a retrospective assessment of short-term and long-term results of combined therapy
with the inclusion of tetracosactide in comparison with other antiepileptic drugs (AED) in West
syndrome. Materials and methods. The research covered 150 children with confirmed West
syndrome treated at Pediatic Clinical Hospital No. 8 (Kazan, Russia) in 2000-2015. The age of
children at the time of research was 4.0-14.5 years. The risk ratio (RR) and their confidence
intervals  (CIs)  were calculated using RevMan 5.0 Software (http://community.cochrane.org).
Differences for p < 0.05 were considered valid. Results and discussion. The children with West
syndrome  were  divided  into  2  groups:  1  st  group  included  90  children  who  received
tetracosactide in combination with other AED, 2 nd group included 60 children who received any
variants of AED excluding tetracosactide. Children in both groups were comparable in age, sex,
neurological status and severity of their disease. After 2 weeks from the start of treatment,
there  were  more  patients  with  complete  control  of  seizures  in  1  st  group  (who  used
tetracosactide) than in 2 nd group (without tetracosactide): 68 of 90 (76 %) patients in 1 st
group, 1 of 60 (2 %) patients - in 2 nd group, RR 45.33, 95 % CI 6.47-317.71, p = 0.0001. After 2
months and 6 months the results were the following: 69 of 90 (77 %) patients in 1 st group, 13
of 60 (22 %) patients in 2 nd group, RR 3.54, 95 % CI 2.16-5.80, p < 0.00001; 69 of 90 (77 %)
patients in 1 st group, 36 of 60 (60 %) patients in 2 nd group; RR 1.28, 95 % CI 1.01-1.62, p =
0.04  respectively.  Long-term  results  of  treatment  (favorable  outcome  -  complete  clinical
remission during 3 years or more) did not differ significantly in both groups: 59 of 90 (66 %)
patients in 1 st group and 37 of 60 (61,6 %) patients in 2 nd group. For long-term outcomes RR
1.12, 95 % CI 0.88-1.42, p = 0.37. Conclusions. The effectiveness of tetracosactide (favorable
outcome - complete absence of seizures) with short-term observation (not less than 6 months)
is higher in comparison with other AED in the absence of difference in safety. The long-term
results of West syndrome treatment (with observation for 3 years or more) in children who
received tetracosactide and in children who received other AED are comparable.
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